Stock Price

Post-acute leader PACS Group reports a landmark year with a 29% revenue jump, fueled by superior patient care metrics and a disciplined expansion strategy.

Perrigo takes a massive $1.3B impairment charge and plans a 7% workforce reduction as it pivots to a 'CORE' business amid a challenging outlook.

With its strategic pivot to high-growth Med Tech paying off, all eyes are on AngioDynamics' CEO presentation at the upcoming Leerink healthcare conference.

Amid record financials and new AI breakthroughs, Cadence's CEO will address investors at a key conference to outline the firm's pivotal role in the AI era.

Facing financial headwinds, Mint Inc. pivots into the high-stakes world of AI, unveiling the FLOKI Minibot M1, a personalized companion for Asia.

Investors sue Corcept Therapeutics, claiming the company hid FDA warnings about its key drug, relacorilant, before a 50% stock price collapse.

With a key gene therapy approval imminent and major clinical data on deck, REGENXBIO's upcoming financial report will be a crucial test for the biotech.

As Aura presents its precision oncology pipeline at key conferences, investors will weigh the promise of its lead drug against a challenging financial landscape.

With its new HAE drug EKTERLY® smashing revenue forecasts, KalVista heads to key conferences where investors will scrutinize its path to profitability.

With its stock lagging, TScan Therapeutics will use a key conference to highlight upcoming clinical trial data and convince investors of its pipeline's value.

After a record 2025 with $51.1M in revenue, the seismic data firm rewards investors, proving its resilience in a volatile Canadian energy market.

The insurer's profits skyrocketed over 1,000% in Q4, signaling a dramatic turnaround fueled by legislative changes and shrewd strategic maneuvers.

AI marketing firm Zeta Global smashes records for the 18th straight quarter, raising guidance and projecting its first full year of GAAP profitability.

With major partnerships and a fresh $130M, Solid Power is scaling up solid-state battery tech. But can it overcome key engineering and financial hurdles?

Fueled by policy incentives and strong demand, First Solar reports robust 2025 growth and accelerates its US factory expansion, cementing its market leadership.

The tech firm announced progress on a major health contract, but with its stock near all-time lows, can this deal deliver a much-needed turnaround?

Thermon Group's $2.2 billion sale to CECO Environmental faces legal scrutiny, leaving shareholders to question if the offer is fair amid record profits.

Fresh off strong 2025 earnings, AtriCure will detail its growth strategy and innovative cardiac portfolio at a major life sciences conference.

Target Hospitality is rapidly expanding workforce housing for AI data centers, revealing the massive, unseen physical infrastructure powering the tech revolution.

As Autolus heads to key investor conferences, its strong AUCATZYL® sales and deep pipeline face scrutiny against mounting losses and a curious PR misstep.